Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.46 |
| ▸ | DRD4 | P21917 | 9/20 | 0.46 |
| ▸ | DRD3 | P35462 | 8/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8282593 | 0.82 | CCR1 (0.43) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL4902867 | 0.82 | HTR1B (0.44) | DRD2DRD4DRD3HTR1BMEN1 | |
| SCHEMBL20381746 | 0.80 | MAPT (0.44) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL14269836 | 0.80 | HTR1B (0.42) | HTR1BHTR1AL3MBTL1ADRA1DADRA1A | |
| SCHEMBL13456503 | 0.79 | L3MBTL4 (0.47) | DRD2DRD4DRD3HTR1BALDH1A1 | |
| SCHEMBL14182464 | 0.79 | CYP3A4 (0.50) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL13412644 | 0.77 | CYP3A4 (0.52) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL16425598 | 0.77 | CYP3A4 (0.52) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL20204118 | 0.76 | DRD2 (0.43) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL21383973 | 0.75 | NPC1 (0.45) | MEN1KMT2AHTR1AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032975-A1 | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes | NPSR1, GABRE, CHRNE | DRD2 135/4885DRD4 292/4885DRD3 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.